research Drug-Induced Hair Loss: Analysis of the Food and Drug Administration’s Adverse Events Reporting System Database
Certain medications, including some immune drugs, contraceptives, and hair loss treatments, are often linked to hair loss.
Search
for
Sort by
Research
150-180 / 1000+ results research Cytokine-Targeting Biologic Therapies for Alopecia Areata: A Comprehensive Review of Mechanism of Action, Clinical Efficacy, and Adverse Events
Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.
research Impact of Reporter Type on Signal Detection of Cancer Therapy–Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
Reporter characteristics affect detection of hair loss from cancer therapy.
research Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
Finasteride use may increase suicidality risk, especially in young men.
research Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
Ixekizumab has known and some unexpected side effects.
research Mining and analysis of adverse event signals of isotretinoin based on the real-world data of FAERS database
Isotretinoin has many serious side effects, including some new ones, needing better safety measures and updated labels.
research Utility of azathioprine, methotrexate and cyclosporine as steroid‐sparing agents in chronic alopecia areata: a retrospective study of continuation rates in 138 patients
Azathioprine is the most continued treatment for chronic alopecia areata over a year, often with added low-dose prednisolone.
research Management of Serious Adverse Events Following Deoxycholic Acid Injection for Submental and Jowl Fat Reduction: A Systematic Review and Management Recommendations
Proper management and preventative measures can reduce serious adverse events from deoxycholic acid injections for fat reduction.
research Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
Reporter characteristics affect detection of hair loss from cancer therapy.
research Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
Afatinib often causes skin problems that need proactive management.
research Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system
Certain medications, especially nervous system drugs, can cause insomnia, with risks varying by age and gender.
research Efficacy and safety of tofacitinib in patients with alopecia areata
Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
research Association of Hair Loss With Suicidality and Psychological Adverse Events vs Finasteride Use
Hair loss, not finasteride, is more strongly linked to psychological issues and suicidality.
research Children and Adolescents with Alopecia Areata: Psychiatric Symptomatology and Life Events: A longitudinal case-control study: Before and During the COVID-19
Children with alopecia areata often face more stress and depression, especially related to separation, which can affect their condition.
research DERMATOLOGICAL ADVERSE EFFECTS OF CHEMOTHERAPEUTIC AGENTS: EXPERIENCE FROM A TERTIARY CENTRE
About 22% of cancer patients had skin-related side effects from chemotherapy, but these were usually not severe enough to halt treatment.
research 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition Attenuates the Adverse Effects of Glucocorticoids on Dermal Papilla Cells
Blocking 11β-HSD1 can lessen the harmful effects of glucocorticoids on hair growth cells.
research Deoxycholic acid in the submental fat reduction: A review of properties, adverse effects, and complications
Deoxycholic acid is effective for reducing chin fat but can cause side effects and serious complications, so careful patient evaluation is needed.
research Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system
Paternal drug exposure can harm fertility, pregnancy outcomes, and offspring health, with specific drugs linked to various reproductive issues.
research Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis
Certain existing drugs, like glycopyrronium and botulinum toxin type A, may help treat excessive sweating.
research Laser-Assisted Drug Delivery: A Systematic Review of Safety and Adverse Events
Laser-assisted drug delivery is generally safe with mostly mild side effects.
research A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
Avacopan may cause unexpected side effects, so early monitoring is important.
research Pharmacotherapy of plexiform neurofibromas in patients with neurofibromatosis type 1. Possible adverse events and their management
Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.
research Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
research Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study
Low-dose finasteride may cause lasting sexual dysfunction and suicidal thoughts in young men.
research Sorafenib-Associated Facial Acneiform Eruption
Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.
research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
research Cemiplimab-Induced Alopecia Areata
A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.
research Sun protection policies and behaviors among U.S. child care centers
Finasteride, a hair loss drug, is linked to increased suicidal thoughts, particularly when used for hair loss.
research Hypertrichosis in females applying minoxidil topical solution and in normal controls
Minoxidil use increases facial hair growth in females, more in older users.
research Dermatologic Care of the Transplant Patient
Transplant patients on immunosuppressive medications have a higher risk of skin cancer, and managing this involves balancing medication with cancer risk.